Republic Services Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? Republic Services Inc. Common Stock trades at $226.87 (market cap $67.34B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Republic Services Inc. Common Stock is far larger — about 18× Tango Therapeutics Inc.'s market cap, and Republic Services Inc. Common Stock pays a 1.22% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals.
| RSG | TNGX | |
|---|---|---|
Market Cap | $67.34B | $3.75B |
Volume | 955,255 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $232.27 | $32.90 |
52-Week Low | $197.73 | $7.50 |
Enterprise Value | $81.53B | $2.77B |
Dividend Yield | 1.22% | — |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.
Read more on RSG →Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →